Upregulation of microRNA miR-652-3p is a prognostic risk factor for hepatocellular carcinoma and regulates cell proliferation, migration, and invasion

References

• Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–2917.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.
   PubMed Web of Science ®Google Scholar
• Venook AP, Papandreou C, Furuse J, et al. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist. 2010;15(Suppl 4):5–13.
   PubMed Web of Science ®Google Scholar
• Hu X, Wang R, Ren Z, et al. MiR-26b suppresses hepatocellular carcinoma development by negatively regulating ZNRD1 and Wnt/β-catenin signaling. Cancer Med. 2019;8(17):7359–7371.
   Web of Science ®Google Scholar
• Stark A, Brennecke J, Russell RB, et al. Identification of drosophila MicroRNA targets. PLoS Biol. 2003;1(3):E60.
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–297.
   PubMed Web of Science ®Google Scholar
• Jin J, Zhang J, Xue Y, et al. miRNA-15a regulates the proliferation and apoptosis of papillary thyroid carcinoma via regulating AKT pathway. Onco Targets Ther. 2019;12:6217–6226.
   PubMed Web of Science ®Google Scholar
• Peng P, Chen T, Wang Q, et al. Decreased miR-218-5p levels as a serum biomarker in bone metastasis of prostate cancer. Oncol Res Treat. 2019;42(4):165–185.
   PubMed Web of Science ®Google Scholar
• Liu Z, Ma M, Yan L, et al. miR-370 regulates ISG15 expression and influences IFN-α sensitivity in hepatocellular carcinoma cells. Cancer Biomarkers. 2018;22(3):453–466.
   PubMed Web of Science ®Google Scholar
• Du W, Zhang X, Wan Z. miR-3691-5p promotes hepatocellular carcinoma cell migration and invasion through activating PI3K/Akt signaling by targeting PTEN. Onco Targets Ther. 2019;12:4897–4906.
   PubMed Web of Science ®Google Scholar
• Wang H, Li X, Li T, et al. Multiple roles of microRNA-146a in immune responses and hepatocellular carcinoma. Oncol Lett. 2019;18(5):5033–5042.
   PubMed Web of Science ®Google Scholar
• Sukata T, Sumida K, Kushida M, et al. Circulating microRNAs, possible indicators of progress of rat hepatocarcinogenesis from early stages. Toxicol Lett. 2011;200(1–2):46–52.
   PubMed Web of Science ®Google Scholar
• Zhu QL, Zhan DM, Chong YK, et al. MiR-652-3p promotes bladder cancer migration and invasion by targeting KCNN3. Eur Rev Med Pharmacol Sci. 2019;23(20):8806–8812.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Hu Y, Shen Q, et al. CircRNA_MYLK promotes malignant progression of ovarian cancer through regulating microRNA-652. Eur Rev Med Pharmacol Sci. 2020;24(10):5281–5291.
   PubMed Web of Science ®Google Scholar
• Li J, Zou X. MiR-652 serves as a prognostic biomarker in gastric cancer and promotes tumor proliferation, migration, and invasion via targeting RORA. Cancer Biomarkers. 2019;26(3):323–331.
   PubMed Web of Science ®Google Scholar
• Liu J, Zhang H, Li X, et al. Diagnostic and prognostic significance of aberrant miR-652-3p levels in patients with acute decompensated heart failure and acute kidney injury. J Int Med Res. 2020;48(11):300060520967829.
   PubMed Web of Science ®Google Scholar
• Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–1474.
   PubMed Web of Science ®Google Scholar
• Chen L, Zhu Q, Lu L, et al. MiR-132 inhibits migration and invasion and increases chemosensitivity of cisplatin-resistant oral squamous cell carcinoma cells via targeting TGF-β1. Bioengineered. 2020;11(1):91–102.
   PubMed Web of Science ®Google Scholar
• Gao F, Wu H, Wang R, et al. MicroRNA-485-5p suppresses the proliferation, migration and invasion of small cell lung cancer cells by targeting flotillin-2. Bioengineered. 2019;10(1):1–12.
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
   PubMed Web of Science ®Google Scholar
• Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4):529–538.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Lei B, Chai W, et al. Increased expression of insulin-like growth factor-1 receptor predicts poor prognosis in patients with hepatocellular carcinoma. Medicine (Baltimore). 2019;98(44):e17680.
   PubMed Web of Science ®Google Scholar
• Janssen HL, Reesink HW, Lawitz EJ, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med. 2013;368(18):1685–1694.
   PubMed Web of Science ®Google Scholar
• Li J, Jin B, Wang T, et al. Serum microRNA expression profiling identifies serum biomarkers for HCV-related hepatocellular carcinoma. Cancer Biomarkers. 2019;26(4):501–512.
   Web of Science ®Google Scholar
• Ding W, Yang H, Gong S, et al. Candidate miRNAs and pathogenesis investigation for hepatocellular carcinoma based on bioinformatics analysis. Oncol Lett. 2017;13(5):3409–3414.
   PubMed Web of Science ®Google Scholar
• Otsuka M, Kishikawa T, Yoshikawa T, et al. MicroRNAs and liver disease. J Hum Genet. 2017;62(1):75–80.
   PubMed Web of Science ®Google Scholar
• Ye Y, Song Y, Zhuang J, et al. MicroRNA-302a-3p suppresses hepatocellular carcinoma progression by inhibiting proliferation and invasion. Onco Targets Ther. 2018;11:8175–8184.
   PubMed Web of Science ®Google Scholar
• Lu J, Lin Y, Li F, et al. MiR-205 suppresses tumor growth, invasion, and epithelial-mesenchymal transition by targeting SEMA4C in hepatocellular carcinoma. FASEB J. 2018;fj201800113R.
   PubMed Web of Science ®Google Scholar
• Zuo ML, Wang AP, Song GL, et al. miR-652 protects rats from cerebral ischemia/reperfusion oxidative stress injury by directly targeting NOX2. Biomed Pharmacother. 2020;124:109860.
   PubMed Web of Science ®Google Scholar
• Gao JD, Li RJ, Ma PL, et al. Knockdown of lncRNA HCP5 protects against cerebral ischemia/reperfusion injury by regulating miR-652-3p. J Biol Regul Homeost Agents. 2020;34(3):893–900.
   PubMed Web of Science ®Google Scholar
• Huang R, Hu Z, Cao Y, et al. MiR-652-3p inhibition enhances endothelial repair and reduces atherosclerosis by promoting Cyclin D2 expression. EBioMedicine. 2019;40:685–694.
   PubMed Web of Science ®Google Scholar
• Jin Y, Yang L, Li X. MicroRNA-652 promotes cell proliferation and osteosarcoma invasion by directly targeting KLF9. Exp Ther Med. 2020;20(4):2953–2960.
   PubMed Web of Science ®Google Scholar
• Xia Z, Yang C, Yang X, et al. miR-652 promotes proliferation and migration of Uveal Melanoma cells by targeting HOXA9. Med Sci Monit. 2019;25:8722–8732.
   PubMed Web of Science ®Google Scholar
• Kowalik MA, Puliga E, Cabras L, et al. Thyroid hormone inhibits hepatocellular carcinoma progression via induction of differentiation and metabolic reprogramming. J Hepatol. 2020;72(6):1159–1169.
   PubMed Web of Science ®Google Scholar
• Fu DZ, Cheng Y, He H, et al. The fate of Kruppel-like factor 9-positive hepatic carcinoma cells may be determined by the programmed cell death protein 5. Int J Oncol. 2014;44(1):153–160.
   PubMed Web of Science ®Google Scholar
• Sun J, Wang B, Liu Y, et al. Transcription factor KLF9 suppresses the growth of hepatocellular carcinoma cells in vivo and positively regulates p53 expression. Cancer Lett. 2014;355(1):25–33.
   PubMed Web of Science ®Google Scholar
• Huang HQ, Chen G, Xiong DD, et al. Down-regulation of microRNA-125b-2-3p is a risk factor for a poor prognosis in hepatocellular carcinoma. Bioengineered. 2021;12(1):1627–1641.
   PubMed Web of Science ®Google Scholar
• Zhang H, Liu S, Chen L, et al. MicroRNA miR-509-3p inhibit metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma. Bioengineered. 2021;12(1):2263–2273.
   PubMed Web of Science ®Google Scholar
• Zhu X, Jiang S, Wu Z, et al. Long non-coding RNA TTN antisense RNA 1 facilitates hepatocellular carcinoma progression via regulating miR-139-5p/SPOCK1 axis. Bioengineered. 2021;12(1):578–588.
   PubMed Web of Science ®Google Scholar